. 2019 May 3;10(33):3093–3103. doi: 10.18632/oncotarget.26886

Table 1. Baseline molecular risk in ALK⁺ NSCLC.

	(% at diangosis)	Metastatic spread	PFS under TKI	OS
V3⁺	30-40%	↑^13,14,16,18	↓^{11,14,18 (12,16)}	↓^{14,18 (16)}
*TP53*^mut	20-25%	(depends on the oncogene)	↓^{18,19 (31)}	↓^{18,19 (17)}
V3⁺*TP53*^mut	6-10%	↑↑¹⁸	↓↓¹⁸	↓↓¹⁸

Frequency of EML4-ALK V3 and TP53 mutations in newly-diagnosed ALK⁺ NSCLC patients and their effect on main clinical characteristics of the disease, based on the collective insight from several studies [11-14,16-19,31].

Abbreviations: PFS: progression free survival, OS: overall survival; TKI: tyrosine kinase inhibitors.

Table 1. Baseline molecular risk in ALK+ NSCLC.

Table 1. Baseline molecular risk in ALK⁺ NSCLC.